Get the Stockscreener App
8.42
5.91%
0.47
After Hours:
7.92
-0.50
-5.94%
Redhill Biopharma Ltd Adr stock is traded at $8.42, with a volume of 11,779.
It is up +5.91% in the last 24 hours and down -0.94% over the past month.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
See More
Previous Close:
$7.95
Open:
$8.08
24h Volume:
11,779
Relative Volume:
0.15
Market Cap:
$10.15M
Revenue:
$35.75M
Net Income/Loss:
$11.57M
P/E Ratio:
-2.2118
EPS:
-3.8069
Net Cash Flow:
$-26.25M
1W Performance:
+5.12%
1M Performance:
-0.94%
6M Performance:
-25.12%
1Y Performance:
-9.24%
1-Day Range:
$7.90
$8.42
1-Week Range:
$7.90
$8.5794
52-Week Range:
$6.80
$82.00
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-11-20 | Initiated | BTIG Research | Buy |
| Jul-12-19 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-12-19 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Jan-26-18 | Initiated | Nomura | Buy |
| Oct-06-17 | Initiated | Seaport Global Securities | Buy |
| Oct-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-17 | Reiterated | FBR & Co. | Outperform |
| Jul-27-16 | Reiterated | FBR Capital | Outperform |
| Sep-29-15 | Initiated | Nomura | Buy |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jun-17-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-15 | Reiterated | ROTH Capital | Buy |
View All
Redhill Biopharma Ltd Adr Stock (RDHL) Latest News
COVID-19 Competitive Landscape 2024 (Updated) - openPR
BARDA funds RedHill's opaganib for Ebola treatment - Investing.com
Medi-Cal extends Talicia access for 15 million Californians - Investing.com
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - StockTitan
Can Redhill Biopharma Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
RDHL stock’s current quarter earnings estimates: What analysts predict? - US Post News
Talicia® Launched in the United Arab Emirates - StockTitan
Taking on analysts’ expectations and winning: Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
Opaganib shows promise in obesity, diabetes treatment - Investing.com India
Balance Sheet Breakdown: Redhill Biopharma Ltd. ADR (RDHL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Redhill Biopharma Ltd. ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo Finance
Its Stock Has Paid Off Big Time For Teck Resources Ltd - SETE News
Are Smart Investors Making the Right Decision? Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Check Out Aveanna Healthcare Holdings Inc (AVAH)’s Trade Data Rather Than the Analysts’ Views - SETE News
RDHL’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Can you now get a good deal on Redhill Biopharma Ltd. ADR’s shares? - US Post News
Is ThredUp Inc (TDUP) positioned for future growth? - SETE News
A look into Redhill Biopharma Ltd. ADR (RDHL)’s deeper side - SETE News
Immuneering Corp (IMRX) expanding its growth trajectory ahead - SETE News
Cipher Mining Inc (CIFR) is looking forward to a strong quarter - SETE News
Nothing is Better Than Hut 8 Corp (HUT) stock at the moment - SETE News
Analytical Overview: Redhill Biopharma Ltd. ADR (RDHL)’s Ratios Tell a Financial Story - The Dwinnex
Redhill Biopharma Ltd. ADR [RDHL] Revenue clocked in at $35.52 million, down -68.49% YTD: What’s Next? - The DBT News
Redhill Biopharma Ltd. ADR Inc. (RDHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Should investors be concerned about RDHL’s high price-to-sales ratio? - US Post News
Exact Sciences Corp. (EXAS) Stock: A Year of Decreases and Increases - The InvestChronicle
New Outlook On Alibaba Group Holding Ltd ADR - Stocks Register
Baker Hughes Co (NASDAQ: BKR) Up 1.26%: This Is What Analysts Are Now Forecasting - Stocks Register
Redhill Biopharma Ltd. ADR (RDHL) requires closer examination - US Post News
Redhill Biopharma Ltd. ADR (RDHL) Stock: A Year of Market Fluctuations - The InvestChronicle
Ratio Examination: Redhill Biopharma Ltd. ADR (RDHL)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com India
Redhill Biopharma Ltd. ADR (RDHL)'s stock performance: a year in review – US Post News - US Post News
RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation - Yahoo Lifestyle UK
Ratio Analysis: Unpacking Redhill Biopharma Ltd. ADR (RDHL)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Should investors be concerned about Redhill Biopharma Ltd. ADR (RDHL)? – US Post News - US Post News
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study - Yahoo News UK
Emerging Technologies in the Proton Pump Inhibitors Market to Hit US$ 3.5 Billion by 2031 - openPR
The Psychology of Redhill Biopharma Ltd. ADR Inc. (RDHL) Price Performance: Understanding Market Sentiment - The InvestChronicle
Proton Pump Inhibitors Market In-depth Analysis, Rising Business Opportunities And Estimated Forecast Till 2031 ... - openPR
Redhill Biopharma Ltd. ADR (RDHL) requires closer examination – US Post News - US Post News
RedHill Biopharma secures $1.25 million in direct offering By Investing.com - Investing.com
KALA Stock Quote Price and Forecast - CNN
RedHill secures new US patent for H. pylori treatment Talicia - Investing.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - Yahoo Finance
LLY Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - PR Newswire
Redhill Biopharma Ltd Adr Stock (RDHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):